United Drug highlights strong growth in interim statement

United Drug has expressed confidence in its ongoing business growth prospects in its new interim management statement.

The medical firm experienced year-on-year growth during the three months ending on December 31st 2012, with much of this expansion coming courtesy of its growing international operations.

Its businesses outside of its native Ireland are now contributing more than 70 percent of group profits and this positive momentum is likely to be accelerated by the five acquisitions announced by United Drug during 2012.

Based on this strong performance, the firm expects constant currency adjusted diluted earnings per share figures for the full year to grow by between five and eight percent compared to last year.

According to the report, this will "leave the group well-positioned to support its future growth objectives both organically and through acquisition".

This comes after the firm announced earlier this week that Annette Flynn has retired as a member of its board of directors at the conclusion of the recent United Drug annual general meeting.